How to Ask Your Doctor for Weight Loss Pills: The Script, the Labs, and the Mistakes That Get You a No

Key Takeaways

• Most denials happen because the patient asks the wrong question or shows up without data, not because the patient doesn't qualify.
• BMI of 30 or higher (or 27 with a weight-related comorbidity) is the FDA threshold for prescription weight-loss medication.
• Bring a 12-month weight log, recent labs (A1C, lipids, TSH), and a list of prior diet attempts to the visit.
• Ask for a specific drug by name, not "something for weight." Specificity signals you've done the homework.
• If your primary care provider says no, the next step is an obesity medicine specialist or a telehealth platform that prescribes off label or compounded options.

Direct answer (40-60 words, snippet-optimized)

To ask your doctor for weight loss pills, schedule a dedicated visit, bring a documented weight history and recent labs, state your BMI plus any weight-related comorbidity, and request a specific medication by name (semaglutide, tirzepatide, phentermine, naltrexone-bupropion, or orlistat). Ask what coverage looks like before leaving the office.

Table of contents

1. The 30-second answer
2. Why most patients get told no
3. What "qualifies" you under FDA criteria
4. The five FDA-approved options to know by name
5. What to bring to the visit
6. The exact script that works
7. Labs your doctor will probably order
8. What to do if your doctor refuses
9. Insurance, prior authorization, and the cost question
10. Telehealth and compounded options
11. Mistakes to avoid
12. FAQ
13. Footer disclaimers

Why most patients get told no

The first reason patients leave a visit empty handed is timing. A weight conversation tacked onto a 15-minute physical for a sore knee gets cut short. The second is missing data. The doctor needs a number, not a story. The third is asking for the wrong thing. "I want Ozempic" lands differently than "I'd like to discuss whether semaglutide is appropriate for my BMI and prediabetes."

A 2023 review of obesity care in primary care settings (Kaplan et al., Obesity 2023) found that fewer than 1 in 5 eligible patients with obesity were ever offered pharmacotherapy. The barrier isn't that doctors think the drugs don't work. It's that obesity remains under coded, under discussed, and under treated in routine visits. You can solve most of that yourself before you walk in.

What "qualifies" you under FDA criteria

The standard threshold for prescription weight loss medication is:

• BMI of 30 or higher, calculated as weight (kg) divided by height squared (m²)
• BMI of 27 to 29.9 with a weight-related comorbidity, including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, polycystic ovary syndrome, or non-alcoholic fatty liver disease

If your BMI is 26 or lower with no comorbidities, FDA-approved obesity drugs are off label. Some clinicians will still prescribe within their judgment. Many won't. Phentermine has a slightly lower threshold in some state guidelines (BMI 27 with a comorbid condition).

A simple BMI lookup before your visit removes ambiguity. Print the number. Write it on a sticky note. Hand it to the doctor if it helps.

The five FDA-approved options to know by name

Knowing the names of the drugs in this class signals seriousness. You don't have to memorize dosing. You do have to know which drug you're asking about and why.

The injectables (Wegovy, Zepbound) produce the largest mean weight loss. The orals are still useful for patients who can't or won't inject, who have contraindications to GLP-1 medications, or who need something cheaper.

For most cash-paying patients in 2026, compounded semaglutide and tirzepatide through a licensed telehealth platform are the most affordable injectable options. Brand-name pricing without coverage runs $940 to $1,400 per month.

What to bring to the visit

Walk in with a folder. Doctors respond to documented patients differently than to vague ones. Bring:

1. A 12-month weight log. Even a phone-app screenshot of monthly weights works. Show that the weight isn't a one-week observation.
2. Recent labs. A1C, fasting glucose, lipid panel, TSH, vitamin D, basic metabolic panel. If you don't have them, ask the front desk to order them before the visit.
3. A list of prior diet and exercise attempts. Specific, dated. "Whole30 for 60 days in 2023, lost 12 lbs, regained 14 over 6 months. Two months of Noom in early 2024, lost 6 lbs, regained 9."
4. Blood pressure readings. Home cuff readings averaged over 7 days are useful evidence of weight-related hypertension.
5. Sleep evidence. A home sleep study report or an Epworth Sleepiness Scale score above 10 supports an obstructive sleep apnea comorbidity.
6. A printout of your BMI calculation with the date and weight used.
7. A specific medication request with two backup options.

This packet often takes 30 minutes to assemble. It doubles your chance of leaving with a prescription.

The exact script that works

Here's a template that opens the conversation cleanly. Adjust the wording to your situation.

> "Doctor, I'd like to spend most of today's visit on weight management. My BMI is 32, I've been at this weight for three years, and my A1C last month was 5.9. I've tried structured diets twice in the last two years and regained both times. I've researched the FDA-approved obesity medications. I'd like to talk about whether semaglutide or tirzepatide would be appropriate for me, and what coverage might look like through my insurance."

What this script does:

• Sets the agenda up front so the visit isn't fragmented
• Anchors with two numbers (BMI and A1C)
• Shows prior diet attempts and the regain pattern
• Names a specific drug class
• Acknowledges the cost conversation before the doctor brings it up

If you can deliver that paragraph in 60 seconds, you've already done more than 80% of patients in obesity visits.

Labs your doctor will probably order

Expect a standard pre-prescribing panel before any GLP-1 prescription:

• Hemoglobin A1C (to document prediabetes or diabetes)
• Basic and complete metabolic panel (kidney function, liver enzymes)
• Lipid panel (LDL, HDL, triglycerides)
• TSH (rule out hypothyroidism as a confounder)
• Vitamin B12 (low B12 affects appetite and fatigue interpretation)
• Pregnancy test for women of childbearing age (GLP-1 medications are contraindicated in pregnancy)

Some clinicians add a thyroid ultrasound or calcitonin level if there's a personal or family history of thyroid disease. The FDA black-box warning for medullary thyroid carcinoma is one of the few absolute contraindications.

If labs are normal, prescribing typically follows within a week. If labs show diabetes or significant cardiovascular risk, your doctor may upgrade the prescription rationale, which improves insurance coverage odds.

What to do if your doctor refuses

Refusals fall into a few buckets. Each has a counter move.

"Diet and exercise should come first." Show the prior attempts in writing. Cite the 2022 American Gastroenterological Association guideline that lifestyle therapy alone should be combined with pharmacotherapy in patients with obesity (Grunvald et al., Gastroenterology 2022). Ask whether your doctor would consider a 90-day trial.

"I'm not comfortable prescribing GLP-1 medications." Ask for a referral to an obesity medicine specialist. The American Board of Obesity Medicine certifies physicians specifically for this. Many regions also have endocrinologists who manage GLP-1 prescriptions.

"Insurance won't cover it." Ask if your doctor will write the prescription anyway and whether they'd document medical necessity for a prior authorization. The prescription is the first step; insurance is a separate fight.

"You're not heavy enough." Recheck the BMI threshold. If you're 27 to 29.9 with a comorbidity, the FDA criteria are met. If you're below 27, the doctor's reluctance is reasonable. Off-label prescribing is at provider discretion.

"Side effects are too risky." Ask which side effects specifically. The mortality data on semaglutide and tirzepatide is favorable. Pancreatitis incidence is roughly 0.3% per year of use. Dose escalation reduces nausea. Most refusals on side effect grounds reflect general caution rather than your individual risk.

If the conversation goes nowhere, change clinicians. The medication exists and is appropriate for many patients whose primary care provider declines to engage.

Insurance, prior authorization, and the cost question

Coverage in 2026 looks like this:

• Commercial plans: Most cover Wegovy or Zepbound for obesity if BMI criteria are met and prior authorization is approved. Tier and copay vary widely.
• Medicare: Part D recently expanded coverage for Wegovy when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and obesity. Coverage purely for weight loss remains rare.
• Medicaid: Most state programs do not cover GLP-1 medications for weight loss. Some states cover them for type 2 diabetes only.

A prior authorization typically requires:

1. Documented BMI at or above the threshold for at least 6 months
2. Documented failed lifestyle intervention (often 3 to 6 months)
3. A weight-related comorbidity if BMI is 27 to 29.9
4. A specific clinical rationale for the chosen agent

If denied, your doctor's office can submit an appeal. Appeals overturn denials roughly 40% of the time when documentation is complete. Manufacturer savings cards (Novo Nordisk for Wegovy, Eli Lilly for Zepbound) reduce copays for eligible commercially insured patients.

Telehealth and compounded options

If your in-person doctor declines or your insurance won't cover the brand-name drug, licensed telehealth platforms are a separate path. A reputable platform should:

• Verify state licensure for the prescribing provider
• Conduct a real clinical intake, not a symptom-only form
• Source from a state-licensed compounding pharmacy that follows USP Chapter 797 / 800
• Document the prescription in a portal you can share with your primary care doctor

Compounded semaglutide and tirzepatide are prepared by a state-licensed compounding pharmacy in response to an individual prescription. They contain the same active ingredient as the brand-name drugs but are not FDA-approved and are not interchangeable with brand-name products. Cost typically runs $179 to $399 per month.

We cover the compounded vs brand-name decision in detail at /articles/compounded-and-peptides/why-compounded-semaglutide-red/.

Mistakes to avoid

• Asking on the way out the door. A weight visit needs its own appointment slot.
• Saying "I want to lose 10 pounds for a wedding." Cosmetic framing closes the FDA-approval door.
• Lying about prior diet attempts. If you say you tried Whole30 and you didn't, your doctor will pick up the inconsistency.
• Asking only about Ozempic. Ozempic is FDA-approved for type 2 diabetes, not weight loss. Wegovy is the obesity-approved version of semaglutide.
• Skipping the labs. Without an A1C and a lipid panel, the visit is incomplete.
• Pushing past a clear no. If your doctor refuses, change clinicians or escalate to specialty care. Don't argue your way to a fractured relationship.

FAQ

What's the easiest weight loss pill to get prescribed?

Phentermine has the longest history and the lowest barrier to prescription in many primary care offices. It's a stimulant, used short term, and effective for 5 to 10% weight loss in most patients. Insurance coverage is generally not required because the cash price is low. GLP-1 medications produce more weight loss but have higher prescribing barriers.

Can I get a weight loss prescription on the first visit?

Yes, often. If you bring labs, a weight log, and meet BMI criteria, many primary care doctors will write a prescription on the first visit. If labs aren't on file, you'll typically have a second visit after the lab draw.

Will my doctor judge me for asking?

Most won't. Obesity is recognized as a chronic disease by the AMA and the WHO. If your doctor seems judgmental, that's a signal to find a new clinician, not to drop the conversation.

What if my BMI is 26?

Most FDA-approved obesity medications require BMI 27 with a comorbidity or BMI 30 alone. At BMI 26, pharmacotherapy is off label. A clinician may still prescribe within judgment, but expect more conversation and potentially out-of-pocket cost.

Are weight loss pills safe?

The FDA-approved options have been studied in tens of thousands of patients. Each has a side effect profile. GLP-1 medications cause nausea and gastrointestinal upset most commonly, with rare risk of pancreatitis. Phentermine raises heart rate and blood pressure. Naltrexone-bupropion can cause headache and insomnia. A clinician matches the drug to your individual risk profile.

How do I bring up weight without it being awkward?

Open with the agenda statement: "I'd like to spend today's visit on weight management." That sentence reframes the visit and removes the hesitation that often kills the conversation in the first 30 seconds.

Can I ask for Ozempic specifically for weight loss?

You can, but Ozempic is FDA-approved for type 2 diabetes, not obesity. The semaglutide version approved for weight loss is Wegovy. Asking for Wegovy by name is more likely to get a productive answer if you don't have type 2 diabetes.

What's the difference between Wegovy and Zepbound?

Wegovy is semaglutide, made by Novo Nordisk, FDA-approved for obesity since 2021. Zepbound is tirzepatide, made by Eli Lilly, FDA-approved for obesity since 2023. Tirzepatide acts on both GLP-1 and GIP receptors and produces larger average weight loss in head-to-head data. Both are weekly injections.

Do I need to see an obesity specialist or can my regular doctor prescribe?

Your primary care doctor can prescribe any FDA-approved obesity medication. An obesity medicine specialist may be more comfortable with dose titration, side effect management, and insurance appeals. If your primary care doctor declines, a specialist referral is the next step.

What labs do I need before getting a GLP-1 prescription?

Standard panels include A1C, complete metabolic panel, lipid panel, and TSH. A pregnancy test is required for women of childbearing age. Some clinicians add vitamin B12 and a urinalysis. Most labs are covered by insurance under preventive care or chronic disease screening.

How long does it take to get approved by insurance?

Prior authorization typically takes 5 to 14 business days. If approved, the prescription is filled at your pharmacy of choice. If denied, your doctor's office can appeal. Appeals add another 2 to 4 weeks.

Can I get weight loss pills through telehealth?

Yes. Licensed telehealth platforms can prescribe FDA-approved obesity medications and, where appropriate, compounded semaglutide or tirzepatide. The intake should include a clinical interview, weight history, and baseline labs. Avoid platforms that prescribe without any clinical contact.

Related guides

• How to Ask Your Doctor for Weight Loss Injections: The Complete Conversation Script
• How to Ask Your Doctor for Weight Loss Pills: The Conversation Framework That Gets to Yes
• Glp1 Eligibility Quiz What Questions Will My Doctor Ask
• Can You Get Zepbound Without a Doctor Prescription? Legal Pathways, Risks, and What Actually Works
• Can You Get Tirzepatide Without a Doctor Prescription? The Legal Reality and What Actually Works
• Can You Get Wegovy Without a Doctor Prescription? The Legal Reality and What Actually Works in 2026

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
3. Grunvald E et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. Gastroenterology. 2022;163:1198-1225.
4. Kaplan LM et al. Perceptions of Barriers to Effective Obesity Care in Primary Care. Obesity. 2023;31:1131-1142.
5. FDA prescribing information: Wegovy, Zepbound, Saxenda, Contrave, Qsymia, Xenical.
6. American Board of Obesity Medicine. Diplomate certification overview, 2024.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
8. CMS coverage update on Wegovy for cardiovascular risk reduction, March 2024.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus LLC. Xenical and Alli are registered trademarks of Cheplapharm and GlaxoSmithKline respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.